Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
12
GTBIF Quote, Financials, Valuation and Earnings
Last price:
$6.20
Seasonality move
:
-13.12%
Day range:
$6.25 - $6.96
52-week range:
$4.63 - $10.43
Dividend yield:
0%
P/E ratio:
34.04x
P/S ratio:
1.29x
P/B ratio:
0.80x
Volume:
475.4K
Avg. volume:
392.8K
1-year change:
-9.9%
Market cap:
$1.5B
Revenue:
$1.1B
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries, Inc.
|
$296.1M | -$0.01 | 0.59% | -100% | $13.63 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835M | $0.56 | 11.9% | 36.21% | $88.87 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
TLRY
Tilray Brands, Inc.
|
$211.1M | -- | 8.44% | -100% | $11.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries, Inc.
|
$6.30 | $13.63 | $1.5B | 34.04x | $0.00 | 0% | 1.29x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$64.08 | $88.87 | $12.3B | 24.01x | $0.00 | 0% | 4.06x |
|
SVRA
Savara, Inc.
|
$5.53 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
TLRY
Tilray Brands, Inc.
|
$7.75 | $11.83 | $899M | -- | $0.00 | 0% | 0.94x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBIF
Green Thumb Industries, Inc.
|
22.08% | -0.134 | 27.88% | 1.19x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
|
TLRY
Tilray Brands, Inc.
|
16.83% | 3.038 | 35.13% | 1.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries, Inc.
|
$137.5M | $36.7M | 1.97% | 2.54% | 12.61% | $57.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
TLRY
Tilray Brands, Inc.
|
$53.1M | -$20M | -84.8% | -98.18% | -9.2% | -$18M |
Green Thumb Industries, Inc. vs. Competitors
-
Which has Higher Returns GTBIF or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 8.17% compared to Green Thumb Industries, Inc.'s net margin of 25.76%. Green Thumb Industries, Inc.'s return on equity of 2.54% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries, Inc.47.18% $0.10 $2.4B ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About GTBIF or ACAD?
Green Thumb Industries, Inc. has a consensus price target of $13.63, signalling upside risk potential of 116.27%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that Green Thumb Industries, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries, Inc.8 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is GTBIF or ACAD More Risky?
Green Thumb Industries, Inc. has a beta of 0.979, which suggesting that the stock is 2.139% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock GTBIF or ACAD?
Green Thumb Industries, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or ACAD?
Green Thumb Industries, Inc. quarterly revenues are $291.4M, which are larger than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Green Thumb Industries, Inc.'s net income of $23.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Green Thumb Industries, Inc.'s price-to-earnings ratio is 34.04x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries, Inc. is 1.29x versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries, Inc.1.29x 34.04x $291.4M $23.8M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns GTBIF or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 8.17% compared to Green Thumb Industries, Inc.'s net margin of 16.99%. Green Thumb Industries, Inc.'s return on equity of 2.54% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries, Inc.47.18% $0.10 $2.4B ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About GTBIF or ALNY?
Green Thumb Industries, Inc. has a consensus price target of $13.63, signalling upside risk potential of 116.27%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Green Thumb Industries, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries, Inc.8 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is GTBIF or ALNY More Risky?
Green Thumb Industries, Inc. has a beta of 0.979, which suggesting that the stock is 2.139% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock GTBIF or ALNY?
Green Thumb Industries, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or ALNY?
Green Thumb Industries, Inc. quarterly revenues are $291.4M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Green Thumb Industries, Inc.'s net income of $23.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Green Thumb Industries, Inc.'s price-to-earnings ratio is 34.04x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries, Inc. is 1.29x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries, Inc.1.29x 34.04x $291.4M $23.8M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns GTBIF or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of 8.17% compared to Green Thumb Industries, Inc.'s net margin of -3.91%. Green Thumb Industries, Inc.'s return on equity of 2.54% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries, Inc.47.18% $0.10 $2.4B BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About GTBIF or BMRN?
Green Thumb Industries, Inc. has a consensus price target of $13.63, signalling upside risk potential of 116.27%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 38.69%. Given that Green Thumb Industries, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries, Inc.8 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is GTBIF or BMRN More Risky?
Green Thumb Industries, Inc. has a beta of 0.979, which suggesting that the stock is 2.139% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock GTBIF or BMRN?
Green Thumb Industries, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or BMRN?
Green Thumb Industries, Inc. quarterly revenues are $291.4M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Green Thumb Industries, Inc.'s net income of $23.8M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Green Thumb Industries, Inc.'s price-to-earnings ratio is 34.04x while BioMarin Pharmaceutical, Inc.'s PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries, Inc. is 1.29x versus 4.06x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries, Inc.1.29x 34.04x $291.4M $23.8M BMRNBioMarin Pharmaceutical, Inc.4.06x 24.01x $786.8M -$30.7M
-
Which has Higher Returns GTBIF or SVRA?
Savara, Inc. has a net margin of 8.17% compared to Green Thumb Industries, Inc.'s net margin of --. Green Thumb Industries, Inc.'s return on equity of 2.54% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries, Inc.47.18% $0.10 $2.4B SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About GTBIF or SVRA?
Green Thumb Industries, Inc. has a consensus price target of $13.63, signalling upside risk potential of 116.27%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that Green Thumb Industries, Inc. has higher upside potential than Savara, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries, Inc.8 0 0 SVRASavara, Inc.6 0 0 -
Is GTBIF or SVRA More Risky?
Green Thumb Industries, Inc. has a beta of 0.979, which suggesting that the stock is 2.139% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock GTBIF or SVRA?
Green Thumb Industries, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or SVRA?
Green Thumb Industries, Inc. quarterly revenues are $291.4M, which are larger than Savara, Inc. quarterly revenues of --. Green Thumb Industries, Inc.'s net income of $23.8M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Green Thumb Industries, Inc.'s price-to-earnings ratio is 34.04x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries, Inc. is 1.29x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries, Inc.1.29x 34.04x $291.4M $23.8M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns GTBIF or TLRY?
Tilray Brands, Inc. has a net margin of 8.17% compared to Green Thumb Industries, Inc.'s net margin of -20%. Green Thumb Industries, Inc.'s return on equity of 2.54% beat Tilray Brands, Inc.'s return on equity of -98.18%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries, Inc.47.18% $0.10 $2.4B TLRYTilray Brands, Inc.24.43% -$0.41 $1.9B -
What do Analysts Say About GTBIF or TLRY?
Green Thumb Industries, Inc. has a consensus price target of $13.63, signalling upside risk potential of 116.27%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $11.83 which suggests that it could grow by 52.58%. Given that Green Thumb Industries, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than Tilray Brands, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries, Inc.8 0 0 TLRYTilray Brands, Inc.2 7 0 -
Is GTBIF or TLRY More Risky?
Green Thumb Industries, Inc. has a beta of 0.979, which suggesting that the stock is 2.139% less volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 2.022, suggesting its more volatile than the S&P 500 by 102.181%.
-
Which is a Better Dividend Stock GTBIF or TLRY?
Green Thumb Industries, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or TLRY?
Green Thumb Industries, Inc. quarterly revenues are $291.4M, which are larger than Tilray Brands, Inc. quarterly revenues of $217.5M. Green Thumb Industries, Inc.'s net income of $23.8M is higher than Tilray Brands, Inc.'s net income of -$43.5M. Notably, Green Thumb Industries, Inc.'s price-to-earnings ratio is 34.04x while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries, Inc. is 1.29x versus 0.94x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries, Inc.1.29x 34.04x $291.4M $23.8M TLRYTilray Brands, Inc.0.94x -- $217.5M -$43.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 23
RingCentral, Inc. [RNG] is down 12.48% over the past day.
Sell
9
FROG alert for Feb 23
JFrog Ltd. [FROG] is down 7.95% over the past day.
Buy
72
SNSE alert for Feb 23
Sensei Biotherapeutics, Inc. [SNSE] is down 2.63% over the past day.
